178 related articles for article (PubMed ID: 37401523)
1. Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
Myhre PL; Liu Y; Kulac IJ; Claggett BL; Prescott MF; Felker GM; Butler J; Piña IL; Rouleau JL; Zile MR; McMurray JJV; Ward JH; Solomon SD; Januzzi JL
Eur J Heart Fail; 2023 Aug; 25(8):1396-1405. PubMed ID: 37401523
[TBL] [Abstract][Full Text] [Related]
2. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
[TBL] [Abstract][Full Text] [Related]
3. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Mohebi R; Liu Y; Felker GM; Prescott MF; Ward JH; Piña IL; Butler J; Solomon SD; Januzzi JL
J Card Fail; 2022 Dec; 28(12):1673-1682. PubMed ID: 36122820
[TBL] [Abstract][Full Text] [Related]
4. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
Mohebi R; Liu Y; Piña IL; Prescott MF; Butler J; Felker GM; Ward JH; Solomon SD; Januzzi JL
J Am Coll Cardiol; 2022 Oct; 80(16):1529-1541. PubMed ID: 36229089
[TBL] [Abstract][Full Text] [Related]
5. Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study.
Omar AMS; Murphy S; Felker GM; Piña I; Butler J; Liu Y; Mohebi R; Bhatia K; Ward JH; Williamson KM; Solomon SD; Januzzi JL; Contreras J
J Card Fail; 2024 May; 30(5):653-665. PubMed ID: 37816446
[TBL] [Abstract][Full Text] [Related]
6. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
7. Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia.
Badreldin HA; Korayem GB; Alenazy BA; Aljohani MH; Alshaya OA; Al Sulaiman K; Alabdelmuhsin L; Alenazi H; Almutairi DM; Alanazi F; Alobathani SK; Alqannam GM; Almadani O; Aljuhani O; Hafiz A; Aljowaie G; Basha E; Alqahtani T; Alhussein M
Medicine (Baltimore); 2023 Dec; 102(51):e36699. PubMed ID: 38134075
[TBL] [Abstract][Full Text] [Related]
8. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
[TBL] [Abstract][Full Text] [Related]
9. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.
Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Solomon SD; Starling RC; Velazquez EJ; Williamson K; Zieroth S; Braunwald E
J Card Fail; 2023 Jun; 29(6):922-930. PubMed ID: 36796671
[TBL] [Abstract][Full Text] [Related]
10. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
[TBL] [Abstract][Full Text] [Related]
11. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Murphy SP; Prescott MF; Camacho A; Iyer SR; Maisel AS; Felker GM; Butler J; Piña IL; Ibrahim NE; Abbas C; Burnett JC; Solomon SD; Januzzi JL
JACC Heart Fail; 2021 Feb; 9(2):127-136. PubMed ID: 33189632
[TBL] [Abstract][Full Text] [Related]
12. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
13. Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction.
Selvaraj S; Claggett BL; Packer M; Zannad F; Anand IS; Pieske B; Zhao Z; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
J Am Heart Assoc; 2021 Sep; 10(17):e022069. PubMed ID: 33998278
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
[TBL] [Abstract][Full Text] [Related]
15. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
Ledwidge M; Dodd JD; Ryan F; Sweeney C; McDonald K; Fox R; Shorten E; Zhou S; Watson C; Gallagher J; McVeigh N; Murphy DJ; McDonald K
JAMA Cardiol; 2023 Apr; 8(4):366-375. PubMed ID: 36884247
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure.
Feng Z; Wang X; Zhang L; Apaer R; Xu L; Ma J; Li X; Che H; Tang B; Xiong Y; Xia Y; Xiao J; Su X; Wang Y; Dou X; Chen J; Mei L; Xue Z; Kong Y; Li S; Zhang H; Lin T; Wen F; Fu X; Tao Y; Fu L; Li Z; Huang R; Ye Z; He C; Shi W; Liang X; Ke G; Liu S
Blood Purif; 2022; 51(3):270-279. PubMed ID: 34753147
[TBL] [Abstract][Full Text] [Related]
17. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
Januzzi JL; Butler J; Fombu E; Maisel A; McCague K; Piña IL; Prescott MF; Riebman JB; Solomon S
Am Heart J; 2018 May; 199():130-136. PubMed ID: 29754651
[TBL] [Abstract][Full Text] [Related]
18. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
Jackson AM; Jhund PS; Anand IS; Düngen HD; Lam CSP; Lefkowitz MP; Linssen G; Lund LH; Maggioni AP; Pfeffer MA; Rouleau JL; Saraiva JFK; Senni M; Vardeny O; Wijkman MO; Yilmaz MB; Saito Y; Zile MR; Solomon SD; McMurray JJV
Eur Heart J; 2021 Sep; 42(36):3741-3752. PubMed ID: 34392331
[TBL] [Abstract][Full Text] [Related]
20. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.
Butt JH; Ibrahim W; Dewan P; Desai AS; Køber L; Prescott MF; Lefkowitz MP; Rouleau JL; Solomon SD; Zile MR; Packer M; Jhund PS; McMurray JJV
Circ Heart Fail; 2023 Mar; 16(3):e010111. PubMed ID: 36943907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
